Human mitochondrial transcription factor A functions in both nuclei and mitochondria and regulates cancer cell growth.

Mitochondrial transcription factor A (mtTFA) is one of the high mobility group protein family and is required for both transcription from and maintenance of mitochondrial genomes. However, the roles of mtTFA have not been extensively studied in cancer cells. Here, we firstly reported the nuclear localization of mtTFA. The proportion of nuclear-localized mtTFA varied among different cancer cells. Some mtTFA binds tightly to the nuclear chromatin. DNA microarray and chromatin immunoprecipitation assays showed that mtTFA can regulate the expression of nuclear genes. Overexpression of mtTFA enhanced the growth of cancer cell lines, whereas downregulation of mtTFA inhibited their growth by regulating mtTFA target genes, such as baculoviral IAP repeat-containing 5 (BIRC5; also known as survivin). Knockdown of mtTFA expression induced p21-dependent G1 cell cycle arrest. These results imply that mtTFA functions in both nuclei and mitochondria to promote cell growth.

[1]  D. Wallace,et al.  The pathophysiology of mitochondrial disease as modeled in the mouse. , 2009, Genes & development.

[2]  Yau-Huei Wei,et al.  Mitochondrial DNA Instability and Metabolic Shift in Human Cancers , 2009, International journal of molecular sciences.

[3]  D. A. Clayton,et al.  Initiation and beyond: multiple functions of the human mitochondrial transcription machinery. , 2006, Molecular cell.

[4]  H. Itoh,et al.  P53 physically interacts with mitochondrial transcription factor A and differentially regulates binding to damaged DNA. , 2003, Cancer research.

[5]  Igor B. Rogozin,et al.  Transcription of mammalian messenger RNAs by a nuclear RNA polymerase of mitochondrial origin , 2005, Nature.

[6]  Y. Sasaguri,et al.  Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines , 2007, Oncogene.

[7]  A. Mayevsky.  Mitochondrial function and energy metabolism in cancer cells: past overview and future perspectives. , 2009, Mitochondrion.

[8]  M. Andreeff,et al.  Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism. , 2009, Cancer research.

[9]  S. Vucetic,et al.  High Mobility Group Protein B1 Is an Activator of Apoptotic Response to Antimetabolite Drugs , 2008, Molecular Pharmacology.

[10]  H. Izumi,et al.  Expression of mitochondrial transcription factor A in endometrial carcinomas: clinicopathologic correlations and prognostic significance , 2010, Virchows Archiv.

[11]  B. Jung-Hynes,et al.  Role of p53 in the anti-proliferative effects of Sirt1 inhibition in prostate cancer cells , 2009, Cell cycle.

[12]  H. Takano,et al.  Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen. , 1999, Cancer research.

[13]  K. Yasumoto,et al.  Activating transcription factor 4 increases the cisplatin resistance of human cancer cell lines. , 2003, Cancer research.

[14]  H. Izumi,et al.  Twist promotes tumor cell growth through YB-1 expression. , 2008, Cancer research.

[15]  Y. Sasaguri,et al.  Ets regulates peroxiredoxin1 and 5 expressions through their interaction with the high‐mobility group protein B1 , 2008, Cancer science.

[16]  Alana Welm,et al.  Cell division and cell survival in the absence of survivin. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Y. Yoshida,et al.  Clinical usefulness of mitochondrial transcription factor A expression as a predictive marker in colorectal cancer patients treated with FOLFOX , 2011, Cancer science.

[18]  Guoying Miao,et al.  Downregulation of survivin by RNAi inhibits growth of human gastric carcinoma cells. , 2007, World journal of gastroenterology.

[19]  G. Barsh,et al.  Mitochondrial transcription factor A is necessary for mtDNA maintance and embryogenesis in mice , 1998, Nature Genetics.

[20]  Bin Han,et al.  Enhanced Expression of PCAF Endows Apoptosis Resistance in Cisplatin-Resistant Cells , 2010, Molecular Cancer Research.

[21]  Carmela Conte,et al.  Oxidative stress-related aging: A role for prostate cancer? , 2009, Biochimica et biophysica acta.

[22]  N. Krynetskaia,et al.  Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage , 2009, Molecular Cancer Therapeutics.

[23]  G. Baffy.  Uncoupling protein-2 and cancer. , 2010, Mitochondrion.

[24]  D. Levy,et al.  Mitochondrial STAT3 Supports Ras-Dependent Oncogenic Transformation , 2009, Science.

[25]  M. P. Holloway,et al.  Aberrant Regulation of Survivin by the RB/E2F Family of Proteins* , 2004, Journal of Biological Chemistry.

[26]  高松 千洋.  Regulation of mitochondrial D-loops by transcription factor A and single-stranded DNA-binding protein , 2002 .

[27]  Michiteru Yoshida,et al.  HMGB proteins and transcriptional regulation. , 2010, Biochimica et biophysica acta.

[28]  Y. Yoshida,et al.  Thioredoxin2 enhances the damaged DNA binding activity of mtTFA through direct interaction. , 2009, International journal of oncology.

[29]  M. Duffy,et al.  Survivin: a new target for anti-cancer therapy. , 2009, Cancer treatment reviews.

[30]  W. Wheaton,et al.  Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity , 2010, Proceedings of the National Academy of Sciences.

[31]  Alain C. Mita,et al.  Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics , 2008, Clinical Cancer Research.

[32]  H. Izumi,et al.  Twist and p53 reciprocally regulate target genes via direct interaction , 2008, Oncogene.